Johnson & Johnson MedTech Announces Labeling Amendment of LINX™ Reflux Management System in the U.S.
CINCINNATI, OH August 7, 2024 – Ethicon*, a Johnson & Johnson MedTech company**, announced today that the U.S. Food & Drug Administration (FDA) has approved a label update to expand the availability of the LINX™ Reflux Management System to include patients with Barrett’s esophagus (BE) experiencing gastroesophageal reflux disease (GERD) symptoms.








